BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 29402125)

  • 1. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD; Rodriguez-Bano J
    Clin Infect Dis; 2017 Apr; 64(7):972-980. PubMed ID: 28362938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
    Bassetti M; Giacobbe DR; Robba C; Pelosi P; Vena A
    Curr Opin Infect Dis; 2020 Dec; 33(6):474-481. PubMed ID: 33060469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
    Aslan AT; Akova M
    Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
    [No Abstract]   [Full Text] [Related]  

  • 5. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
    Bouxom H; Fournier D; Bouiller K; Hocquet D; Bertrand X
    Int J Antimicrob Agents; 2018 Jul; 52(1):100-103. PubMed ID: 29580930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
    Watkins RR; Deresinski S
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
    [No Abstract]   [Full Text] [Related]  

  • 13. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
    Montravers P; Bassetti M
    Curr Opin Infect Dis; 2018 Dec; 31(6):587-593. PubMed ID: 30299359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.